SciELO - Scientific Electronic Library Online

 
vol.49 número2Interferón alfa 2b recombinante más ribavirina en el tratamiento de la hepatitis crónica C índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Artigo

Indicadores

  • Não possue artigos citadosCitado por SciELO

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista Cubana de Medicina

versão On-line ISSN 1561-302X

Resumo

DORTA GURIDI, Zaily et al. Tolerance to treatment with standard interferon and ribavirin in patients presenting with cirrhosis from hepatitis C. Rev cubana med [online]. 2010, vol.49, n.2, pp. 0-0. ISSN 1561-302X.

In treatment of compensating hepatic cirrhosis of viral etiology the maintained viral response with Interferon and Ribavirin is minor and it is accompanied of a greater frequency of adverse effects in relation to non-cirrhotic patients. However, due to the scarce therapeutical options for this group of patients and the need to retard the appearance of complications, was the reason of present paper. Authors present the results from a group of 36 patients diagnosed with hepatic cirrhosis from HCV in A Child's stage included in multicenter clinical trials, sponsored by the Institute of Gastroenterology; patients received a therapeutical scheme of Interferon alfa-2b plus Ribavirin during 48 weeks assessing their tolerance by clinical and hematologic adverse events. Results demonstrate that this treatment alternative is safe and well-tolerated.

Palavras-chave : Treatment; hepatic cirrhosis by hepatitis C virus.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License